Jubilant gets USFDA nod for Drax Exametazime

Updated: Mon, Aug 21, 2017
05:14 pm
PTI
RELATED NEWS
Monetary Policy announcements exhibit continuity and stability - Expert Ajay Bagga tells Anil Singhvi Monetary Policy announcements exhibit continuity and stability - Expert Ajay Bagga tells Anil Singhvi
RBI Monetary Policy Review: Shaktikanta Das led panel keeps policy rates unchanged RBI Monetary Policy Review: Shaktikanta Das led panel keeps policy rates unchanged
Infosys Chairman Nandan Nilekani on India's Digital Economy I Kotak Institutional Equities highlights details Infosys Chairman Nandan Nilekani on India's Digital Economy I Kotak Institutional Equities highlights details

Drug firm Jubilant Life Sciences today said it has received new drug application approval from the US health regulator for Drax Exametazime.

Jubilant Pharma Ltd, a wholly-owned subsidiary of the company, through its Canada-based arm Jubilant Draximage Inc has received new drug application (NDA) approval from the United States Food and Drug Administration (USFDA) for Drax Exametazime, Jubilant Life Sciences said.

"This approved NDA is indicated for leukocyte (white blood cell) labelled scintigraphy as an adjunct in the localisation of intra-abdominal infection and inflammatory bowel disease," it said in a BSE filing.

This is the sixth approval the company has received from the USFDA during the current financial year, it added.

Shares of Jubilant Life Sciences closed 1.33 per cent down at Rs 695 on BSE.

 

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.